explore -WSS

explore

author：focus 2025-10-01 08:21:21 - browse：356

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Cano Health’s bankruptcy is a warning for Medicare Advantage

WSS

Colonoscopy at 40? Study finds a possible benefit

Why drug prescriptions should include diagnoses

New guidelines on severe brain injury complicate already difficult decisions

Texas Medical Board asked to define abortion emergency exception

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Why drug prescriptions should include diagnoses

focus

explore

focus

Jerome Adams on the need for new antivirals for Covid

The story of mRNA: From a loose idea to a tool that may help curb Covid

At least 13 dead in Texas as scorching temps continue

Ask STAT: What do you want to know about ChatGPT in medicine?

What does generative AI mean for health care? We asked experts

Gene therapy has helped boys walk. Can scientists keep it that way?

As demand for Covid shots wanes, Moderna seeks its next success

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

State Dept. review finds Biden bears some blame for Afghanistan failures

The Biogen Aduhelm mess could happen again

Wikipedia

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Death of patient in Alzheimer’s trial raises question of possible risks

Death of patient in Alzheimer’s trial raises question of possible risks

Donald Trump's relentless attacks on special counsel Jack Smith

Donald Trump's relentless attacks on special counsel Jack Smith

With FDA staff opposed to Sarepta therapy, top official intervened

focus

knowledge

explore

explore